Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Abbott Xience DES For Short Dual-Antiplatelet Course

Executive Summary

The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.

You may also be interested in...



Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication

The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.

Two Studies Support Short Dual Antiplatelet Therapy With Abbott’s Xience DES

Results from two trials confirm patients at high risk of bleeding treated with Abbott’s Xience stent can be safely treated with short regimens of dual antiplatelet therapy.

Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic

The company announced the US launch of the AcQCross Qx transseptal dilator/needle. It is specifically designed to help deploy Boston Scientific’s Watchman left-atrial appendage closure device, but it is part of the left-heart access device portfolio that Acutus recently sold to Medtronic.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT144166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel